Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences (NASDAQ: ENVB) has announced positive findings from preclinical studies that support the metabolic profile of its leading candidate, EB-373. The absorption, distribution, metabolism, and excretion (ADME) as well as toxicology assays have demonstrated rapid conversion of EB-373 to the active metabolite psilocin. These results are consistent with previous animal pharmacokinetic..